Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $589.1 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 24.74% year-over-year to $589.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 billion (down 19.22% YoY) and the FY2025 annual result came in at $589.1 million, down 24.74% from the prior year.
• Liabilities and Shareholders Equity fell to $589.1 million in Q4 2025 per AUTL's latest filing, from $661.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for AUTL reached as high as $901.4 million in Q1 2024 and fell as low as $263.8 million in Q3 2022.
• A 5-year average of $529.5 million and a median of $455.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 108.51% — and 2025, when it dropped 24.74%.
• Year by year, Liabilities and Shareholders Equity stood at $405.6 million in 2021, then grew by 20.89% to $490.3 million in 2022, then slipped by 23.43% to $375.4 million in 2023, then soared by 108.51% to $782.7 million in 2024, then slipped by 24.74% to $589.1 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $589.1 million, $661.9 million, and $721.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.